TiGenix, which is developing injectable stem cell therapies for the treatment of perianal fistulas, filed on Tuesday with the SEC to raise up to $58 million in an initial public offering.
The Leuven, Belgium-based company, which was founded in 2000 and booked $8 million in sales for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol TIG. Canaccord Genuity and Nomura Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
